Fig. 6: Differential internalization activated by octreotide and paltusotine.
From: Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine
a, b Effects of N2766.55A or F2947.35A mutation on the internalization of SSTR2 in HEK293 cells treated with octreotide (a) and paltusotine (b) measured by ELISA assays by detecting the expression of SSTR2 on the cell surface. Data represent mean ± SEM from three independent experiments. c, d Effects of N2766.55A or F2947.35A mutation on the internalization of SSTR2 in HEK293 cells treated with octreotide (c) and paltusotine (d) indicated by confocal fluorescence microscopy. eGFP-tagged SSTR2 wild-type or mutant plasmid was transfected in HEK293 cells and then cells were treated with 10 μM octreotide or paltusotine for 30 min and analyzed by confocal fluorescence microscopy (green, eGFP-SSTR2; blue, DAPI). Scale bar, 50 μm.
